What is the current stock price of Kiniksa Pharmaceuticals, Ltd. (KNSA)?

As of the latest market data, Kiniksa Pharmaceuticals, Ltd. (KNSA) is trading at $53.24. The stock has seen a loss of -0.76% today.

Does Kiniksa Pharmaceuticals, Ltd. (KNSA) pay a dividend?

Based on current data, Kiniksa Pharmaceuticals, Ltd. does not have a confirmed active dividend policy.

What is the market cap of Kiniksa Pharmaceuticals, Ltd.?

The current market capitalization of Kiniksa Pharmaceuticals, Ltd. (KNSA) is approximately unavailable.

KNSA

Kiniksa Pharmaceuticals, Ltd.·Healthcare

53.24

0.764%(−0.41)

Market Closed

57.00

7.062%(+3.76)

After Hours

Last Updated: — ET

52W L: $26.2752W H: $59.87

KNSA NEWS

seekingalpha.com

Apr 29

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.

fool.com

Apr 29

Breakfast News: Enphase Dips As Solar Demand Dims

Enphase suffers from weaker U.S. demand, Fiverr jumps on Q1 earnings beat, and more

fool.com

Apr 28

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.

seekingalpha.com

Apr 28

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

zacks.com

Apr 28

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

globenewswire.com

Apr 28

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Sector

Healthcare

Industry

Biotechnology

Employees

315

IPO Date

2018-05-25

Beta

0.17

Websitewww.kiniksa.com↗